Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload

Acute Heart Failure Clinical Trial

— DRAIN-AHF  

Official title:

Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload - A Randomized Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06166654
• Other study ID #: DRAIN_AHF
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: April 1, 2024
• Est. completion date: March 31, 2027

Study information

• Verified date: December 2023
• Source: Copenhagen University Hospital, Hvidovre
• Contact: Johannes Grand, MD, Phd, MPH
• Phone: +4522817126
• Email: johannes.grand[@]regionh.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aim to identify the best strategy for treating acute heart failure (AHF) with volume overload, particularly focusing on patients resistant to standard loop-diuretics. The trial is a double-blinded, randomized, controlled, multicenter study. Its primary objective is to compare the efficacy of loop-diuretics combined with either Metolazone or Acetazolamide, against loop-diuretics alone. The trial will also determine the optimal type of loop-diuretic to use. Eligible participants include adults over 18 years hospitalized with AHF and volume overload, showing signs of congestion and at risk of diuretic resistance. Exclusions apply to those with acute coronary syndrome, low systolic blood pressure, prior renal therapy, or previous treatment with Acetazolamide or Metolazone. The primary outcome is the number of days alive and out-of-hospital by day 30. Secondary outcomes include a composite clinical benefit at 30 days, Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, and successful decongestion 72 hours post-inclusion. The trial aims to enroll about 1,041,939 patients across three treatment arms over three years. The minimal important difference is set as a reduction in out-of-hospital days by at least two days, with an anticipated low dropout rate. The study's power is calculated to be 80% with an adjusted alpha level for comparing the three diuretic groups.

Description:

Trial synopsis Title: OPTIMAL DIURETIC THERAPIES FOR ACUTE HEART FAILURE WITH VOLUME OVERLOAD - A RANDOMIZED CLINICAL TRIAL Background: Intravenous loop-diuretics have been the key component in treating acute heart failure (AHF) since the nineteen sixties and has a Class 1 recommendation in the 2021 ESC guidelines for heart failure. Hospitalization for AHF with volume overload is the most frequent cause of hospital admission among elderly patients and is associated with poor outcome. There is a high need for additional decongestant therapies beyond the recommended use of intravenous loop diuretics. Primary objective: To determine the superior strategy of loop-diuretics + Metolazone, loop-diuretics + Acetazolamide, or loop-diuretics without additional diuretics during in-hospital treatment for acute decompensated heart failure with volume overload and diuretic resistance. Furthermore, to determine optimal type of loop-diuretic. Hypothesis: One of the three diuretic strategies are superior to the others for decongesting acute heart failure with volume overload. Design: Investigator-initiated, double-blinded, randomized, controlled, multicenter, interventional clinical trial of acute decompensated heart failure patients at risk for diuretic resistanseresistance. Intervention: - Acetazolamide as add-on to loop-diuretics - Metolazone as add-on to loop diuretics - Usual care including guideline-recommended increase in loop-diuretic dose and fluid and salt-restriction. Inclusion criteria: 1. Age ≥ 18 years 2. Acute hospital admission with a clinical diagnosis of acute heart failure with volume overload. 3. At risk of diuretic resistance 4. Clinical signs of congestion Exclusion criteria: 1. Acute coronary syndrome 2. Systolic blood pressure <85 mmHg 3. Use of renal replacement therapy or ultrafiltration in-hospital before study inclusion 4. Treatment with acetazolamide or metolazone during hospitalization prior to randomization Primary outcome: Days alive out-of-hospital to day 30. Secondary outcomes: 1. Clinical benefit at 30 days, consisting of a composite of 1. all-cause death, 2. Readmisison after discharge from initial hospitalization, 3. new receipt of renal-replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value ≥200% of the baseline value), assessed using a Hierarchical win-ratio' approach. 2. Kansas City Cardiomyopathy Questionnaire (KCCQ) at 30 days 3. Successful decongestion 72 hours after inclusion (measured as the decongestion score ad modum Advor)

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 939
• Est. completion date: March 31, 2027
• Est. primary completion date: March 31, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years

2. Acute hospital admission with a clinical diagnosis of acute heart failure with volume overload.

3. At risk of diuretic resistance

4. Clinical signs of congestion

Exclusion Criteria:

1. Acute coronary syndrome

2. Systolic blood pressure <85 mmHg

3. Use of renal replacement therapy or ultrafiltration in-hospital before study inclusion

4. Treatment with acetazolamide or metolazone during hospitalization prior to randomization

Related Conditions & MeSH terms

• Acute Heart Failure
• Heart Failure

Intervention

Drug:
• Acetazolamide
1. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.
• Metolazone 2.5 MG
2. 2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.

Other:
• Double-placebo
This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).

Locations

Country	Name	City	State
Denmark	Amager-Hvidovre Hospital	Hvidovre	Capital Region Of Denmark

Sponsors (1)

Lead Sponsor	Collaborator
Johannes Grand

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Days alive out-of-hospital to day 30	Days alive out-of-hospital to day 30	30 days
Secondary	Win ratio of 1. all-cause death, 2. Readmisison, 3. renal-replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value =200% of the baseline value), assessed using a Hierarchical win-ratio' approach.	Number of Clinical benefit at 30 days, consisting of a composite of 1. all-cause death, 2. Readmisison after discharge from initial hospitalization, 3. new receipt of renal-replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value =200% of the baseline value), assessed using a Hierarchical win-ratio' approach.	30 days
Secondary	Kansas City Cardiomyopathy Questionnaire	Kansas City Cardiomyopathy Questionnaire (KCCQ). Minimum and Maximum Values: The KCCQ is scored on a scale from 0 to 100.; Interpretation of Scores: Higher Scores: Indicate better heart failure-related quality of life, fewer symptoms, and fewer physical and social limitations.; Lower Scores: Suggest more severe heart failure symptoms, greater physical limitations, and a poorer quality of life.	30 days
Secondary	Decongestion score 72 hours after inclusion	scale from 0 to 10 on the basis of the sum of scores for the degree of edema (0 to 4), pleural effusion (0 to 3), and ascites (0 to 3), with higher scores indicating a worse condition on all scales	72 hours